Austrian deeptech startup Sarcura secures €7 million to revolutionize cell therapy manufacturing

Published on November 17, 2022

The Austrian deeptech startup Sarcura just closed an oversubscribed €7 million Seed Plus funding round to develop a next-generation cell therapy manufacturing platform. Founded in 2019, Sarcura is developing an instrument platform for the manufacturing of advanced cell therapies. Their platform combines silicon chip technology and microfluidic processing to enable real-time process control and manipulation…

This content is for members only. Visit the site and log in/register to read.

The post Austrian deeptech startup Sarcura secures €7 million to revolutionize cell therapy manufacturing appeared first on EU-Startups.

Continue reading on website
Other news

Why You Need to Look at HR Data the Way You Look at Your Finances

November 17, 2022
People are a company's greatest asset, and it's time for HR departments to follow finance's lead in sharing key information with owners/managers.

7 Telltale Signs You're Ready to Quit the Rat Race and Become an Entrepreneur

November 17, 2022
Grasping the right time to jump on brave alterations is essential to success. Here are seven signs you no longer have an employee mentality.